- Home
- CANF vs ELSE Comparison
CANF vs ELSE Comparison
Compare CANF & ELSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ELSE
- Stock Information
- Founded
- CANF 1994
- ELSE 1968
- Country
- CANF Israel
- ELSE United States
- Employees
- CANF N/A
- ELSE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ELSE Industrial Machinery/Components
- Sector
- CANF Health Care
- ELSE Industrials
- Exchange
- CANF Nasdaq
- ELSE Nasdaq
- Market Cap
- CANF 13.5M
- ELSE 14.7M
- IPO Year
- CANF N/A
- ELSE N/A
- Fundamental
- Price
- CANF $1.03
- ELSE $4.71
- Analyst Decision
- CANF Strong Buy
- ELSE
- Analyst Count
- CANF 2
- ELSE 0
- Target Price
- CANF $14.00
- ELSE N/A
- AVG Volume (30 Days)
- CANF 83.3K
- ELSE 30.6K
- Earning Date
- CANF 08-29-2025
- ELSE 08-08-2025
- Dividend Yield
- CANF N/A
- ELSE N/A
- EPS Growth
- CANF N/A
- ELSE 14.32
- EPS
- CANF N/A
- ELSE 0.11
- Revenue
- CANF $674,000.00
- ELSE $9,368,000.00
- Revenue This Year
- CANF $461.72
- ELSE N/A
- Revenue Next Year
- CANF N/A
- ELSE N/A
- P/E Ratio
- CANF N/A
- ELSE $43.55
- Revenue Growth
- CANF N/A
- ELSE 7.01
- 52 Week Low
- CANF $0.98
- ELSE $3.65
- 52 Week High
- CANF $4.69
- ELSE $5.50
- Technical
- Relative Strength Index (RSI)
- CANF 42.43
- ELSE 53.50
- Support Level
- CANF $1.00
- ELSE $4.51
- Resistance Level
- CANF $1.05
- ELSE $4.85
- Average True Range (ATR)
- CANF 0.02
- ELSE 0.15
- MACD
- CANF 0.00
- ELSE -0.01
- Stochastic Oscillator
- CANF 40.00
- ELSE 48.39
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ELSE Electro-Sensors Inc.
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.